TT virus and hepatitis G virus infections in Korean blood donors and patients with chronic liver disease

Table 1 The prevalence of TTV and HGV infections in blood donors and patients with chronic liver disease from Korea

Subject	n	TTV (%)	HGV (%)	TTV & HGV (%)
Healthy blood donors	110	9 (8.2)	2 (1.8)	0 (0.0)
HBsAg (+) donors	112	18 (16.1)a	2 (1.8)	0 (0.0)
Anti-HCV (+) donors	69	14 (20.3)a	12 (17.4)b	3 (4.3)
Patients with type	81	17 (21.0)a	11 (13.6)b	6 (7.4)
B chronic liver disease
Chronic hepatitis	6	10 (21.7)	5 (10.9)	3 (6.5)
Liver cirrhosis	15	3 (20.0)	3 (20.0)	2 (13.3)
Hepatocellular carcinoma	20	4 (20.0)	3 (20.0)	1 (5.0)
Patients with type	19	4 (21.1)a	2 (10.5)b	1 (5.3)
C chronic liver disease
Chronic hepatitis	10	2 (20.0)	1 (10.0)	0 (0.0)
Hepatocellular carcinoma	9	2 (22.2)	1 (11.1)	1 (11.1)
Total	391	62 (15.9)	29 (7.4)	10 (2.6)

^aP < 0.05 vs healthy blood donors,

^bP < 0.05 vs healthy blood do-nors or HBsAg-positive donors.

Table 2 Transfusion history according to the detection of TTV and HGV in patients with chronic liver disease

Group		n	Transfusion history
			Yes (%)	No (%)
TTV	Positive	21	14 (66.7)a	7 (33.3)
	Negative	77	33 (42.9)	44 (57.1)
HGV	Positive	13	10 (76.9)	3 (23.1)
	Negative	85	37 (43.5)	48 (56.5)
Total		98	47 (48.0)	51 (52.0)

^aP < 0.05 vs TTV-or HGV-negative patients.